Selective use of sentinel lymph node surgery during prophylactic mastectomy
Open Access
- 18 September 2006
- Vol. 107 (7) , 1440-1447
- https://doi.org/10.1002/cncr.22176
Abstract
BACKGROUND. Patients with invasive cancer identified at the time of prophylactic mastectomy (PM) will require axillary lymph node dissection for staging; therefore, many surgeons advocate sentinel lymph node (SLN) surgery at the time of PM. The current study investigates the invasive cancer rate in PM and evaluates factors associated with invasive cancer to guide SLN surgery use. METHODS. Patients undergoing PM at the M. D. Anderson Cancer Center between January 2000 and July 2005 were identified from a prospective database. Clinical, radiographic, and pathologic data were collected. RESULTS. A total of 409 patients (436 PM cases) were identified; 382 underwent contralateral PM (CPM) and 27 underwent bilateral PM (BPM). Cancer was identified in 22 of 436 PM cases (5%). Of these, 14 patients (64%) had ductal carcinoma in situ (DCIS). Only 8 patients (1.8%) had invasive cancer, with a mean tumor size of 5 mm (range, 2–9 mm). There was no difference in the occult cancer rate between CPM and BPM. No cases of invasive cancer were identified in the 23 patients with BRCA mutations. Significantly increased risk of invasive cancer in the PM breast was seen in postmenopausal patients (3.7%; P = .007), patients age >60 years (7.5%; P = .008), and patients with history of invasive lobular carcinoma (9.7%; P = .0002) or lobular carcinoma in situ (LCIS) (7.7%; P = .008). CONCLUSIONS. The frequency of cancer in PM is very low and the majority represents DCIS. Therefore, routine use of SLN surgery in all patients undergoing PM is not warranted. However, patients at higher risk for whom SLN surgery should be considered include older women and patients with a history of lobular cancer or LCIS. Cancer 2006. © 2006 American Cancer Society.Keywords
This publication has 26 references indexed in Scilit:
- Surgical Complications Associated With Sentinel Lymph Node Biopsy: Results From a Prospective International Cooperative Group TrialAnnals of Surgical Oncology, 2006
- Impact of concurrent proliferative high‐risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast‐conserving therapyCancer, 2005
- Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancerBreast Cancer Research and Treatment, 2005
- Comprehensive Axillary Evaluation in Neoadjuvant Chemotherapy Patients With Ultrasonography and Sentinel Lymph Node BiopsyAnnals of Surgical Oncology, 2005
- Allergic Reactions to Isosulfan Blue in Sentinel Lymph Node MappingThe Breast Journal, 2005
- Cytokeratin‐positive cells in sentinel lymph nodes in breast cancer are not random eventsCancer, 2004
- Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study GroupJournal of Clinical Oncology, 2004
- Role for Sentinel Lymph Node Dissection in the Management of Large (≥5 cm) Invasive Breast CancerAnnals of Surgical Oncology, 2001
- Epidemiology of Breast Cancer in Older WomenDrugs & Aging, 2001
- Benefit of Prophylactic Mastectomy for Women With BRCA1 or BRCA2 MutationsPublished by American Medical Association (AMA) ,2000